A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease
- 14 March 2006
- journal article
- research article
- Published by Wolters Kluwer Health in Neurology
- Vol. 66 (5) , 664-671
- https://doi.org/10.1212/01.wnl.0000201252.57661.e1
Abstract
Background: Creatine and minocycline were prioritized for testing in Phase II clinical trials based on a systematic evaluation of potentially disease modifying compounds for Parkinson disease (PD).Keywords
This publication has 34 references indexed in Scilit:
- Hereditary Early-Onset Parkinson's Disease Caused by Mutations in PINK1Science, 2004
- The combination of randomized and historical controls in clinical trialsPublished by Elsevier ,2004
- Minocycline enhances MPTP toxicity to dopaminergic neuronsJournal of Neuroscience Research, 2003
- Minocycline and doxycycline are not beneficial in a model of Huntington's diseaseAnnals of Neurology, 2003
- Creatine and Cyclocreatine Attenuate MPTP NeurotoxicityExperimental Neurology, 1999
- Effect of lazabemide on the progression of disability in early Parkinson's diseaseAnnals of Neurology, 1996
- The Cloning and Expression of a Human Creatine TransporterBiochemical and Biophysical Research Communications, 1994
- Mitochondrial Complex I Deficiency in Parkinson's DiseaseJournal of Neurochemistry, 1990
- Effect of Deprenyl on the Progression of Disability in Early Parkinson's DiseaseNew England Journal of Medicine, 1989
- Calibrated phase II clinical trials in oncologyStatistics in Medicine, 1986